Pembrolizumab Activity in BCG-Refractory Papillary Bladder Cancer
Pembrolizumab monotherapy showed promising antitumor activity for patients with high-risk non–muscle invasive bladder cancer that did not respond to standard treatment with BCG.
Source: medscape.com